Suggestions
Ram Aiyar
Professional based in Greater Boston
Ram Aiyar, Ph.D., MBA, is the Chief Executive Officer and President of Korro Bio, Inc., a biotechnology company specializing in RNA editing therapies. He has nearly two decades of experience in the biotech and pharmaceutical industries, where he has worked across various stages of development, from clinical trials to commercialization.
Career Overview
Before joining Korro Bio in November 2020, Aiyar co-founded Corvidia Therapeutics, where he served as Chief Financial Officer and Chief Business Officer. He played a pivotal role in the company's growth and led its acquisition by Novo Nordisk for $2.1 billion. His previous roles include positions at BioHealth Innovation as an entrepreneur-in-residence, and leadership roles at FlowMetric Inc., Sofinnova Partners, and J.P. Morgan Chase.
Aiyar began his scientific career in research at Janssen Pharmaceuticals' immunology group and has a robust background in corporate development, finance, and strategy.
Education
Ram Aiyar holds a Master of Science (M.S.) and a Ph.D. in Electrical and Computer Engineering from Drexel University, along with an MBA in Finance and Business Strategy from INSEAD (France/Singapore) .123
Contributions to Korro Bio
At Korro Bio, Aiyar is focused on advancing the company's proprietary RNA editing platform, OPERA (Oligonucleotide Promoted Editing of RNA), which aims to treat diseases by repairing mutations at the RNA level. His leadership is expected to drive innovation in genetic medicine, particularly targeting conditions that have been difficult to treat with traditional approaches .24
Highlights
It's a big day for Korro as we nominated our first development candidate (KRRO-110), and the potential best-in-class therapy it brings for patients with Alpha 1 Anti-trypsin Deficiency (AATD).
We believe we can bring AATD patients to as close to "normal" (>50% editing of RNA with >70% of normal A1AT in preclinical mouse models).
We look forward to working with our clinical advisors, including Dr. Jeff Teckman who has seen this program from its inception.
#RNAEditing $KRRO #KorroBio #AATD #KorroKrew
Completed an unbelievable journey to the top of Africa’s tallest mountain - Mt. Kilimanjaro @19.3k ft. Along the journey, raised >$1M for cancer research at the Fred Hutch under the leadership of Luke Timmerman, met 20 other amazing biotech executives from across the US and learned about their journeys, and an amazing crew of Tanzanians without whose support this would not have been possible.
Thank you to my major sponsors Goodwin, Stifel Financial Corp. and Cresa for supporting this endeavor. I would also like to thank and appreciate the countless individuals who have lent their support including the Krew at Korro Bio, Inc.
This was a first for me on multiple levels and much like developing a novel class of drugs, requires both a mental grit and physical strength to do hard things. Watch out for the folks in this group to accomplish big things!
#AlpineAscents #FredHutch #AlwaysNeedAKrew #AfricaAdventures
